Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

Status Recruiting

Clinical Trial Summary

Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in otherwise healthy adult patients. Outcome measure was biopsy proven resolution of the carcinoma.

Clinical Trial Description

Importance: Skin cancer is the most common cancer in the United States, with more people diagnosed each year than all other cancers combined. Basal cell and squamous cell cancers are the most common forms with an estimated 6-7 million cases diagnosed annually. Costs of treating these cancers in the U.S. are estimated at $9-10 billion annually. Task force consensus guidelines suggest Mohs surgery as the treatment of choice, and as the single most precise and effective treatment method. However, cost and issues of cosmesis are principal disadvantages. Previous studies show the effectiveness of a topical solution of ascorbic acid in the treatment of BCC. This study extends previous work to evaluate efficacy in the treatment of SCC of the skin. Objective: To evaluate efficacy of a therapeutic regimen in treating squamous cell cancer, consisting of 30% ascorbic acid in 95% dimethylsulfoxide topically applied at home by patients twice a day for 8 weeks, vs 5% imiquimod cream which is an FDA approved treatment for SCC. Design, Setting, and Participants: This study was carried out in accordance with principles of the Declaration of Helsinki. Detailed informed consent was obtained from each patient. Eligible participants of any age had histologically confirmed primary, previously untreated, nodular or superficial SCC. Patients with cancers larger than 2 cm or deeper than 2 mm were excluded from the study. Imiquimod was applied once daily for 5 days per week as per manufacturer instructions for treatment of SCC. Patients were randomly assigned to treatment group. Participants and outcome assessors were blinded to treatment protocol. Patients were seen at initial visit, 4 weeks, 8 weeks, and six weeks after treatment conclusion for final biopsy. The AA treatment was a solution while the IMQ a cream, however participants were simply told they would be receiving a topical treatment with instructions on how to apply, thus the blinding was intact. Main Outcomes and Measures Number of lesions out that were cancer free after 8 wks of treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05932511
Study type	Interventional
Source	Center for Biomedical Research, Inc.
Contact
Status	Recruiting
Phase	Early Phase 1
Start date	June 12, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02213133` - Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas	Phase 2
Not yet recruiting	`NCT04533321` - A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Active, not recruiting	`NCT01232374` - Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Withdrawn	`NCT01148082` - School Response to Families Who Have Children With Cancer	N/A
Completed	`NCT01208883` - A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer	Phase 1
Completed	`NCT01089803` - Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer	N/A
Terminated	`NCT00707655` - Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy	Phase 1/Phase 2
Completed	`NCT00793169` - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed	`NCT00586040` - Photochemical Tissue Bonding	Phase 2
Completed	`NCT01127737` - Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients	N/A
Completed	`NCT00409565` - A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer	Phase 2
Completed	`NCT00176267` - Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer	Phase 2
Terminated	`NCT04685798` - Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT	N/A
Recruiting	`NCT04370587` - A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04475952` - Early Diagnosis of Upper Digestive Tract Disease
Recruiting	`NCT04435938` - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT05852665` - Buccal Cancer Resection Ultrasound Guided	N/A
Recruiting	`NCT05048459` - Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease	N/A
Suspended	`NCT03952585` - De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer	Phase 2/Phase 3